POSTERIOR SEGMENT EYE DISORDERS MARKET ANALYSIS
Global Posterior Segment Eye Disorders Market: Key Developments
In November 2021, Alcon acquired Ivantis, Inc. to expand its product portfolio by adding Hydrus Microstent for surgical glaucoma. Hydrus Microstent is one of the key products in Canada. With this acquisition, Alcon will increase its presence in the market.
In October 2021, Roche received approval from the U.S. FDA for Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with neovascular or “wet” age-related macular degeneration.
In February 2021, Topcon Healthcare launched its new Glaucoma Module which simplifies the diagnosis of glaucoma. These product launches are likely to increase the demand of the drugs and devices for the treatment of posterior segment eye disorders in the country.
In February 2020, IRIDEX Corporation launched a second generation of the MicroPulse P3 Device for glaucoma which is intuitive and easy to use, and as per the company, over 120,000 patients have been treated in over 60 countries with the original version of the MicroPulse P3 Device which is further expected to increase with the launch of the newer and advanced device.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
